Three oncofusions are included in the favorable risk subgroup of AML: PML::RARA AML is characterized by a fusion between PML, a nuclear protein with a variety of functions, and retinoic acid receptor α (RARA), a nuclear receptor and transcription factor (4–7). Here, RARA is linked to acute myeloid leukemia.